...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Reply New Message
Back To Forum List View
Icon president Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
8
BearDownAZ
Sep 01, 2018 10:59PM
Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
5
Nextblockbuster
Sep 02, 2018 12:14PM

Bear, 

Great find i only wish Zenith would release these type of publications in a NR,

Not sure why management is not releasing an NR, just might get more interest from future investors or Pharma potential  partners 

 

 

2 Recommendations
Icon president Re: Modulating ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
5
BearDownAZ
Sep 02, 2018 12:27PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply